Tachykinin receptors and tachykinin receptor antagonists

Journal of Autonomic Pharmacology

Volumn 13, Issue 1, 1993, Pages 23-93

  Maggi, Carlo Alberto ^a   Patacchini, Riccardo ^a   Rovero, Paolo ^a   Giachetti, Antonio ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; ACETYLLEUCYLASPARTYLGLUTAMINYLTRYPTOPHYLPHENYLALANYLGLYCINAMIDE; CYCLO(GLUTAMINYLTRYPTOPHYLPHENYLALANYLGLYCYLLEUCYLMETHIONYL); ELEDOISIN; FR 113680; KASSININ; L 668169; MDL 29913; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; NEUROKININ A; NEUROKININ A [3-10][3 LYSINE 8 GLYCINE GAMMA LACTAM 9 LEUCINE]; NEUROKININ A [4-10][5 TYROSINE 6,8,9 DEXTRO TRYPTOPHAN 10 ARGININE]; NEUROKININ A [4-10][5 TYROSINE 6,8,9 DEXTRO TRYPTOPHAN 10 LYSINE]; NEUROKININ B; NEUROPEPTIDE K; PHYSALAEMIN; PHYSALAEMIN[9 DEXTRO PROLINE SPIRO GAMMA LACTAM 10 LEUCINE 11 TRYPTOPHAN]; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SENKTIDE; SPANTIDE; SUBSTANCE P; SUBSTANCE P METHYL ESTER; TACHYKININ; TACHYKININ DERIVATIVE; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIN 62577;

HUMAN; INFLAMMATION; NERVOUS SYSTEM; NEUROTRANSMISSION; NONHUMAN; REVIEW; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMAL; HUMAN; MOLECULAR SEQUENCE DATA; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, TACHYKININ; TACHYKININS;

EID: 0027397351     PISSN: 01441795     EISSN: 13652680     Source Type: Journal    
DOI: 10.1111/j.1474-8673.1993.tb00396.x     Document Type: Review

References (518)

1. Effect of synthetic tachykinin analogues on airway mocrovascular leakage in rats and guinea‐pigs: evidence for the involvement on NK‐1 receptors
2. Microvascular leakage induced by substance P in rat urinary bladder: involvement of cyclooxygenase metabolites of arachidonic acid
3. Effects of tachykinins and selective tachykinin receptor agonists on vascular permeability in the rat lower urinary tract: evidence for the involvement of NK‐1 receptors
4. Neurokinin A (NK‐2) receptor revisited with SR 48,968 a potent nonpeptide antagonist
5. 9]NKA to NK‐2 receptors on hamster urinary bladder
6. Novel non‐petide substance P antagonists in the rat. Soc
7. The co‐localisation of substance P and VIP in cholinergic type terminals of the rat parotid gland
8. Selective localization of vasoactive intestinal polypeptide and substance P in human eosinophils
9. Sensory neuropeptides: species variations in effects on the blood‐aqueous barrier regional blood flows and pupillary sphincter muscle
10. NK‐1 receptor mediation of neurogenic plasma extravasation in rat skin
11. Imidazo [4,5‐b]quinoxaline cyanines as neurokinin antagonists
12. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system
13. Histamine‐releasing activity of endogenous peptides on mast cells derived from different sites and species
14. 25‐induced mediator release from different mast cells subtypes of rat and guinea‐pig
15. An examination of the pharmacology of two substance P antagonists and the evidence for tachykinin receptor subtypes
16. 7,9] substance P as tachykinin partial agonists in the rat colon
17. Effect of selective tachykinin receptor antagonists on capsaicin and TKs‐induced bronchospasm in anaesthetized guinea‐pigs
18. Preprotachykinin gene expression in the human basal ganglia: characterization of mRNAs and premRNAs produced by alternate RNA splicing
19. Neuropeptides and nasal secretion
20. Substance P and neurokinin A in human nasal mucosa
21. Substance P and neurode‐generative disorders. A speculative review
22. Substance P and multiple sclerosis
23. Asthma as an axon reflex
24. Neuropeptides and airway pathophysiology
25. Human bronchial secretion—effect of substance P, muscarinic and adrenergic stimulation in vitro
26. The presence of NK‐3 tachykinin receptors on rat uterus
27. Search for a physiological role of stubstance P in gastroin‐testinal motility
28. Evidence for an involvement of substance P but not cholecystokinin‐like peptides, in hexamethonium‐resistant intestinal peristalsis
29. Tachykininergic transmission to the circular muscle of the guinea‐pig ileum: evidence for the involvement or NK‐2 receptors
30. Neurokinin A, neurokinin B and neuropeptide K in the rabbit iris: a study comparing different extraction methods
31. Investigation into species variants in tachykinin NK‐I receptors by use of the non‐peptide antagonist, CP 96345
32. Investigation into differences in tachykinin NK‐1 receptors between and within species using a peptide and a non‐peptide NK‐1 receptor antagonist
33. Evidence for central and peripheral nervous system interaction with mast cells
34. Profile of activity of the NK‐1 receptor antagonist, GR 82,334 in acute nociceptive tests
35. The non‐peptide NK‐I receptor antagonist (|Mp) CP 96,345 produces antinociceptive and anti‐oedema effects in the rat
36. Effect of SP/bombesin antagonists on the release of growth hormone by GHRP and GHRH
37. Inhibition of smooth muscle contractions induced by capsaicin and electrical transmural stimulation by a substance P antagonist
38. Neurokinin A with potassium channel blockade potentiates contraction to electrical stimulation in human bronchus
39. Comparative effects of neurokinin A (NKA) and neuropeptide γ (NPγ) in human isolated bronchus
40. A cDNA encoding the precursor of the rat neuropeptide neurokinin B
41. The substance P receptor subtype modulating cate cholamine release from adrenal chromaffin cells
42. Antinociceptive effects of racemic RP 67,580 but not racemic CP 96,345 on acetic acid‐induced writhing and formalin paw in mice
43. An examination of the selectivity of a new nonpeptide tachykinin antagonist
44. Clinical and inflammatory responses to exogenous tachykinins in allergic rhinitis
45. Tachykinin multiplicity in rat central nervous system as studied using antisera raised against substance P and neurokinin
46. 25I]‐histidine‐neurokinin A binds selectivity to NK‐2 receptors of the B type in rat small intestine smooth muscle membranes
47. A conformational approach to the discovery of potent and selective neurokinin receptor antagonists
48. Tachykinin actions on alveolar macrophages
49. Tachykinins activate guinea‐pig alveolar macrophages: involvement of NK‐2 and NK‐1 receptors
50. Differential binding of CP 96,345 across species: possible heterogeneity of the NK‐1 tachykinin receptor
51. Novel pharmacology of substance K binding sites: a third type of tachykinin receptor
52. 10]. neurokinin A(4–10) (MDL 28,564) distinguishes tissue tachykinin peptide NK‐2 receptors
53. Pharmacologic characterization and autoradiographic distribution of binding sites for iodinated tachykinins in the rat central nervous system
54. Agonist and antagonist binding to tachykinin peptide NK‐2 receptors
55. Tachykinin and their receptors: pharmacology biochemistry and molecular biology advance a neuropeptide story to the forefront of science
56. Pharmacologic examination of capsaicin‐induced contractions of guinea‐pig isolated trachea
57. Substance P in the adrenal gland: origin and species distribution
58. Molecular characterisation, expression and localisation of human neurokinin 3 receptor
59. Neuropeptide y, the most potent contractile tachykinin in human isolated bronchus, acts via a ‘non‐classical’ NK‐2 receptor
60. Multiple tachykinin binding sites in hamster rat and guinea‐pig urinary bladder
61. Characterization and autoradiographic localization of multiple tachykinin binding sites in gastrointestinal tract and bladder
62. Neuropeptide y‐preferring subtypes of NK‐2 receptors in rat fundus and dog urinary bladder. Soc
63. Concepts in characterization of tachykinin receptors
64. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion
65. Sympathectomy enhances the substance P‐mediated breakdown of the blood aqueous barrier in response to infrared irradiation of the rabbit iris
66. 2 are inhibited by a substance P antagonist
67. Pupillary supersensitivity to substance P following prolonged treatment with tetrodotoxin or substance P antagonists
68. Structure expression and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A neuropeptide K and neuropeptide
69. Conformationally constrained tachykinin analogs which are selective ligands for the eleidosin binding site
70. Effects of CGRP neurokinin A and neurokinin A (4–10) on the mitogenic response of human peripheral blood mononuclear cells
71. Autoradiographic mapping of substance P receptors in lung
72. Aminoacid sequence of substance P
73. Selective agonists of NK‐2 binding sites highly active on rat portal vein (NK‐3 bioassay)
74. Chemometric approach to a QSAR study of peptides behaving as NK‐2 receptor antagonists
75. Affinity and stability of some substance P agonists in rat and guinea‐pig: a comparative study in central and peripheral tissues
76. Effects of capsaicin on inflammation and on the substance P content of nervous tissues in rats with adjuvant arthritis
77. Inhibition of tachykinin‐induced hypotension in dogs by CP‐96, 345, a selective blocker of NK‐1 receptors
78. Histochemistry of the enteric nervous system
79. Substance P enteric neurons mediate non‐cholinergic transmission to the circular muscle of the guinea‐pig intestine
80. Characterization of the peripheral action of neurokinins and neurokinin receptor selective agonists on the rat cardiovascular system
81. Probing peptide backbone function in bombesin
82. Characterization of substance P‐like immunoreactivity and tachykinin encoding mRNAs in rat medullary thyroid carcinoma cell lines
83. Intramural neurones of the guinea‐pig urinary bladder: histochemical localization of putative neurotransmitters in culture and newborn animals
84. Substance P: a carotid body peptide
85. y‐Preprotachykinin‐(72–92) peptide amide: an endogenous preprotachkinin I gene‐derived peptide that preferentially binds to neurokinin 2 receptors
86. Conversion of NPK to neurokinin A and vesicular localization of neurokinin A and substance P in neurons of the guinea‐pig small intestine
87. Modifications of drinking behaviour and or arterial blood pressure induced by tachykinins in rats and pigeons
88. Dactinomycin is a competitive NK‐2 receptor antagonist
89. Cigarette smoke‐induced airway oedema is blocked by the NK‐1 antagonist, CP 96, 345
90. Substance K and substance P differentially modulate mesolimbic and mesocortical systems
91. 1) receptors
92. Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin‐induced contractions of guinea‐pig isolated trachea
93. Nasal response to substance P and methacholine in subjects with and without allergic rhinitis
94. Phylogeny of tachykinin receptor localization in the vertebrate central nervous system: apparent absence of NK‐2 and NK‐3 binding sites in the human brain
95. In vitro and in vivo release of neurokinin A‐like immunoreactivity from rat substantia nigra
96. Characterization of neurokinin receptors in various isolated organs by the use of selective agonists
97. Receptors for neurokinins in human bronchus and urinary bladder are of the NK‐2 type
98. Structure‐activity study of neurokinins. Antagonists for the NK‐2 receptor
99. Neurokinins produce selective vaso‐constriction via NK‐3 receptors in the rat mesenteric vascular bed
100. Different receptors are involved in the endothelium‐mediated relaxation and the smooth muscle contraction of the rabbit pulmonary artery in response to substance P and related neurokinins
101. Effects of peptides and non‐peptides on isolated arterial smooth muscles: role of endothelium
102. Intestinal peristalsis associated with release of immunoreactive substance P
103. Specific agonists for neurokinin B receptors
104. Antagonists for the neurokinin NK‐3 receptor evaluated in selective receptor systems
105. Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat
106. Noxious heating of the skin releases immunoreactive substance P in the substantia gelatinosa of the cat: a study with antibody microprobes
107. In vitro effects of substance P on neonatal rat sympathetic preganglionic neurones
108. Tachykinin‐mediated modulation of the primary antibody response in rats: evidence for mediation by an NK‐2 receptor
109. Direct evidence that capsaicin‐induced plasma protein extravasation is mediated through tachykinin NK‐1 receptors
110. NK‐2 tachykinin receptors in the guinea‐pig renal pelvis
111. Effects of capsaicin pretreatment on neuropeptides and salivary secretion of rat parotid glands
112. Nonadrenergic noncholinergic salivary secretion in the ferret
113. Super‐sensitivity to substance P and physalaemin in rat salivary glands after denervation or decentralization
114. Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors
115. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area
116. Behavioural effects of tachykinins and related peptides
117. A potent and selective nonpeptide antagonist of the neurokinin A (NK‐2) receptor
118. The tachykinin peptide family
119. 11] substance P, a neuropeptide antagonist, blocks binding, calcium mobilizing and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells
120. RP 67,580, a nonpeptide substance P antagonist: comparison with other antagonists and affinities in different animal species
121. Binding profile of RP 67,580, a new non‐peptide SP antagonist: comparison with CP 96,345
122. 3H] substance P binding in rat and guinea‐pig shown by the use of peptide agonists and antagonists
123. Plasma extravasation in the cat knee joint induced by antidromic articular nerve stimulation
124. Extravasation in the knee induced by antidromic stimulation of articular C fibre afferents of the anesthetized cat
125. Arthritis and the nervous system
126. Effect of antagonists selective for NK‐1 and NK‐2 receptors on somatosensory responses of rat dorsal horn neurones
127. The involvement of neurokinin receptor subtypes in somatosensory processing in the superficial dorsal horn of the cat
128. NK‐1 and NK‐2 neurokinin receptors characterized in the rat isolated urinary bladder preparation
129. Biological evaluation of SP antagonists
130. Chemical design of antagonists of substance P
131. Differential activation of intracellular effector by two isoforms of human neurokinin 1 receptor
132. Resiniferatoxin, capsaicin and CGRP‐evoked porcine coronary vasodilatation is independent of EDRF mechanisms but antagonized by CGRP(8–37)
133. 11]‐substance P (Spantide) and somatostatin and interaction with tyrotropin releasing hormone
134. Tachykinin receptors and the airwarys
135. Effect of novel SP antagonist, FK 888 on airway constriction and airway edema in guinea‐pigs
136. Effects of actinomycin D on airway constriction induced by tachykinins and capsaicin in guinea‐pigs
137. Supersensitivity of the rabbit iris sphincter muscle induced by trigeminal denervation: the role of substance
138. Substance P mediates neurogenic vasodilatation in extrinsically denervated guinea‐pig submusocal arterioles
139. Effects of three mammalian tachykinins on single enteric neurons
140. Substance P release from spinal cord slices by capsaicin
141. Immunoreactive substance P in sympathetic ganglia: distribution and sensitivity toward capsaicin
142. Substance P antagonists in substantia nigra are anticonvulsant
143. Pharmacology properties of a potent and selective nonpeptide substance P antagonist
144. RP 67,580 a potent and selective non‐peptide SP antagonist
145. Tachykinin receptors mediating airway macromolecular secretion
146. Radioiodinated substance P, neurokinin A and eledoisin bind predominantly to NK‐1 receptors in guinea‐pig lung
147. A novel substance P binding site in bovine adrenal medulla
148. The human neurokinin A (substance K) receptor
149. Human substance P receptor (NK‐l): organization of the gene, chromosome localization and functional expression of cDNA clones
150. Stable expression of high affinity NK‐1 (substance P) and NK‐2 (neurokinin A) but low affinity NK‐3 (neurokinin B) receptors in transfected CHO cells
151. Sialic acid is selectively involved in the interaction of agonists with M2 muscarinic acetylcholine receptors
152. Species differences in affinities of nonpeptide antagonists for substance P receptors
153. NK‐2 tachykinin receptors and contractions of circular muscle of the human colon: characterization of the NK2 receptor subtype
154. Tachykinin receptor antagonists and non‐cholinergic activation of motility in the guinea‐pig proximal colon
155. NK‐1 receptors mediate the tachykinin stimulation of salivary secretion: selective agonists provide further evidence
156. Neurokinins induce a relaxation of the rat duodenum in vivo by activating postganglionic sympathetic elements in prevertebral ganglia: involvement of an NK‐2 type of neurokinin receptor
157. Characterization of the tachykinin NK‐2 receptor in the human urinary bladder by means of selective antagonists
158. Release of substance P from the cat spinal cord
159. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation
160. Isolation and characterization of the human lung NK‐2 receptor gene using rapid amplification of cDNA ends
161. Differences between central and peripheral actions of substance P and substance P (1–9) nonapeptide
162. 11]substance P on endothelin‐1 binding sites in rat cardiac membranes
163. Interaction of the non‐peptide NK‐1 tachykinin receptor antagonist (|Mp)CP 96,345 with L‐type calcium channels in rat cerebral cortex
164. Tachykinin receptor types: classification and membrane signalling mechanisms
165. 125I] iodohistidyl‐neurokinin A label multiple tachykinin receptors in rat brain
166. Effects of capsaicin pretreatment on the inflammatory response to scalding injury in the rat
167. A spirolactam conformationally‐constrained analogue of physalaemin which is a peptidase resistant, selective NK‐1 receptor agonist
168. GR71, 251 a novel, potent and highly selective antagonist at neurokinin NK‐1 receptor
169. The central pressor actions of a novel tachykinin peptide, y preprotachykinin (72–92)‐peptide amide
170. The discovery of a tripeptide substance P antagonist and its structure‐activity relationship
171. 7,9] substance P
172. Effects of substance P and neurokinin A (substance K) on motor behavior: unique effect of substance P attributable to its amino‐terminal sequence
173. Roles for substance P in central regulation of blood pressure and heart rate
174. Novel selective agonists and antagonists conform neurokinin NK‐1 receptors in guinea‐pig vas deferens
175. 2 NH)] analogs of neurokinin A(4–10)
176. Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism
177. Spinal action of neurokinins producing cardiovascular responses in the conscious, freely moving rat: evidence for a NK1 receptor mechanism
178. Influence of substance P on the response of guinea‐pig ileum to transmural nerve stimulation
179. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors and regulatory mechanisms
180. The effect of substance P on the regional lymphonode antibody response to antigenic stimulation in capsaicin‐pretreated rats
181. Immunoreactive substance P release from skin nerves in the rat by noxious thermal stimulation
182. Demonstration of a neurokinin A receptor subytpe in transfected fibroblasts
183. Discussion of nomenclature for tachykinins and tachykinin receptors
184. Molecular characterization of a functional cDNA encoding the rat substance P receptor
185. 7,9] substance P an analogue with substance P antagonistic activity
186. 7,9]SP, inhibits inflammatory responses in the rabbit eye
187. Local effector functions of capsaicin‐sensitive sensory nerve endings: involvement of tachykinins, CGRP and other neuropeptides
188. Ascending enteric reflex: multiple neurotransmitter systems and interactions
189. A tachykinin antagonist inhibits gastric emptying and gastrointestinal transit in the rat
190. Sensory neurons mediate protective vasodilatation in rat gastric mucosa
191. Gastric mucosal protection against ulcerogenic factors in the rat mediated by capsaicin‐sensitive afferent neurons
192. Multiple roles of tachykinins in the ascending enteric reflex
193. In vivo and in vitro actions of mammalian tachykinins
194. Enkephalinase inhibitor potentiates substance P‐ and capsaicin‐induced bronchial smooth muscle contractions in humans
195. Effects of lithium and haloperidol administration on the rat brain levels of substance P
196. Isolation and characterization of the human lung NK‐ I receptor cDNA
197. Mucosal nerves in endobronchial biopsies in asthma and non‐asthma
198. Comparison of cardiovascular and bronchoconstrictor effects of substance P, substance K and other tachykinins
199. Capsaicin induced release of multiple tachykinins (substance P, neurokinin A and eledoisin‐like material) from guinea‐pig spinal cord and ureter
200. Multiple tachykinins (neurokinin A, neuropeptide K and substance P) in capsaicin‐sensitive sensory neurons in the guinea‐pig
201. Effects of haloperidol and clozapine on preprotachykinin A messenger RNA tachykinin tissue levels release and neurokinin 1 receptors in the striato‐nigral system
202. Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5 hydroxytryptamine metabolism
203. Specific binding of substance P aminoterminal heptapeptide [SP(1–7)] to mouse brain and spinal cord membranes
204. Characterization of ligand‐binding properties and selectivities of three rat tachykinin receptors by transfection and functional expression of their cloned cDNAs in mammalian cells
205. Substance K excites dopaminergic and nondopaminergic neurons in rat substantia nigra
206. Receptors mediating tachykinin‐induced contractile responses in guinea‐pig trachea
207. Comparison of the apparent affinity of GR 82,334 at NK‐1 receptors in various tissue preparations
208. Receptors mediating the contractile response to neurokinin agonists in the guinea‐pig trachea
209. The possible role of neuropeptides in the pathophysiology of rheumatoid arthritis
210. Central actions of substance P and related tachykinins
211. Pharmacology of the tachykinin system
212. Trophic effect of various neuropeptides on the cultured ventral spinal cord of rat embryo
213. Capillary permeability induced by intravenous neurokinins, receptor characterization and mechanism of action
214. Mast cells show electrophysiological response to very low levels of substance P without degranulation
215. Characterization of the ability of various substance P antagonists to inhibit action of bombesin
216. A synthetic peptide that is a bombesin receptor antagonist
217. Tachykinin antagonists inhibit the morphine withdrawal response in guinea‐pigs
218. Thyroid hormone regulates tachykinin gene expression in rat anterior pituitary
219. Release of substance P‐like immunoreactivity in dog paw lymph after scalding injury
220. Neurokinin receptors antagonists: old and new
221. Neurokinin in a human pheocromocytoma measured with a specific radioimmunoassay
222. Characterization of the substance P receptor in tunicamycin‐treated transfected cells using a photoaffinity analog
223. Interactions between neuropeptides and dopamine neurons in the ventromedial mesencephalon
224. Regional distribution of substance P, neurokinin A and neurokinin in rat central nervous system
225. Different substance P receptors are found on mucosal epithelial cells and submucous neurons of the guinea‐pig small intestine
226. Substance P in principal sympathetic neurons: regulation by impulse activity
227. Substance P levels differ in sympathetic target organ terminals and ganglion perikarya
228. Effect of substance P on nicotine‐induced desensitization of cultured bovine adrenal chromaffin cells: possible receptor subtypes
229. Alterations in cat knee joint blood flow induced by electrical stimulation of articular afferents and efferents
230. Neurogenic influences in arthritis
231. Elevated levels of substance P in intraocular fluid in proliferative vitreoretino‐pathy
232. Distribution of neurokinin A‐like and neurokinin B‐like immunoreactivity in human peripheral tissues
233. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases
234. Distribution of substance P‐immunoreactive and CGRP‐immunoreactive nerves in normal human lungs
235. A substance P antagonist blocks noncholinergic slow excitatory postsynaptic potential in guinea‐pig sympathetic ganglia
236. Effect of substance P and its C‐terminal hexapeptide on gastric and pancreatic secretion in the dog
237. Structure and gene organization of bovine neuromedin K precursor
238. Stimulatory effect of substance P on sympathetic ganglia and spinal cord in culture
239. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A
240. Precursor forms of substance P (SP) in nervous tissue: detection with antisera to SP, SP‐Gly and SP‐Gly‐Lys
241. Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis
242. Evidence of NK‐1 and NK‐2 tachykinin receptors and their involvement in histamine release in a murine mast cell line
243. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn
244. Substance P‐like immunoreactivity in adrenal chromaffin cells and intra‐adrenal nerve fibres of rats
245. Tachykinin‐induced anion secretion in guinea‐pig distal colon: role of neural and inflammatory mediators
246. Inhibition of carrageenen induced inflammation in the rat knee joint by substance P antagonist
247. Mediators of substance P induced inflammation in the rat knee joint
248. Neurokinin B is a preferred agonist for a neuronal substance P receptor and its action is antagonized by enkephalin
249. Selective agonists of tachykinin binding sites. Fund
250. A specific substance P antagonist blocks smooth muscle contractions induced by noncholinergic nonadrenergic nerve stimulation
251. Tachykinin receptor antagonists and modulation of micturition reflex in rats
252. Role of NK‐1 tachykinin receptors in thermonociception: effect of (|Mp)‐CP 96,345, a nonpeptide substance P antagonist on the hot plate test in mice
253. The possible existence of multiple receptors for substance P
254. Multiple tachykinin binding sites in peripheral tissues and in brain
255. Inhibition of neurogenic plasma exudation in guinea‐pig airways by CP‐96,345 a new non‐peptide NK‐1 receptor antagonist
256. Increase of substance P in primary afferent nerves during chronic pain
257. The non peptide tachykinin antagonist, CP‐96,345 is a potent inhibitor of neurogenic inflammation
258. Substanz P and speichelsekretion
259. Intraneuronal substance P contributes to the severity of experimental arthritis
260. 11] substance P, a new selective radioligand for the NK‐1 receptor
261. Effect of endothelium on the actions of sympathetic and sensory nerves in the perfused rat mesentery
262. Calcium‐dependent potassium‐stimulated release of neurokinin A and neurokinin B from rat brain regions in vitro
263. Regional distribution and in vivo release of tachykinin‐like immunoreactivity in rat brain: evidence for regional differences in relative proportions of tachykinins
264. In vivo release of substance P in the nucleus tractus solitarii increases during hypoxia
265. Tachykinin release from rat spinal cord in vitro and in vivo response to various stimuli
266. Intragastric capsaicin enhances rat gastric acid elimination and mucosal blood flow by afferent nerve stimulation
267. Neuropeptides and their peptidases: functional considerations
268. Presence of various carbohydrate moieties including β‐galactose and N‐aceylglucosamine residues on solubilized porcine brain neurokinin‐a/ substance P receptors
269. Substance P interactions with the nicotinic response
270. An isolated growth cone‐enriched fraction from developing rat brain has substance P binding sites
271. Ultra‐structural localization of serotonin and substance P in vascular endothelial cells of rat femoral and esenteric arteries
272. Characterization of neurokinin receptors in guinea‐pig urinary bladder smooth muscle: use of selective neurokinin antagonists
273. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis
274. Effect of neuropeptides on production of inflammatory cytokines by human monocytes
275. 125I]NKA binding due to NK‐2 receptor activation
276. Substance P immunoreactive sensory nerves in the lower respiratory tract of various mammals including man
277. Dactinomycin inhibits noncholinergic broncho‐constriction by capsaicin‐sensitive sensory nerves in the guinea‐pig by antagonizing neurokinin 2 receptor activation
278. Substance P and capsaicin induced contraction of human bronchi
279. Polypeptide‐containing neurons in airway smooth muscle
280. Origin and distribution of capsaicin‐sensitive substance P‐immunoreactive nerves in the nasal mucosa
281. Multiple tachykinins are produced and secreted upon posttranslational processing of the three substance P precursor proteins, α‐, β‐ and γ‐preprotachykinin
282. Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors
283. Pharmacological specificity of synthetic peptides as antagonists at tachykinin receptors
284. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK‐1) receptor antagonist
285. Capsaicin‐sensitive nerves in the gastrointestinal tract
286. Tachykinin receptors in the airways and lung: what should we block
287. The pharmacology of the efferent function of sensory nerves
288. The role of peptides in the regulation of micturition reflex: an update. Gen
289. Therapeutic potential of capsaicin‐like molecules: studies in animals and humans
290. Effect of thiorphan on the response of guinea‐pig isolated urinary bladder to exogenous and endogenous tachykinins
291. Cystometric evidence that capsaicin‐sensitive nerves modulate the afferent branch of micturition reflex in humans
292. Cutaneous lesions in capsaicin‐pretreated rats—a trophic role of capsaicin‐sensitive afferents
293. Heterogeneity of NK‐2 tachykinin receptors in hamster and rabbit smooth muscles
294. Tachykinin‐like immunoreactivity in the mammalian urinary bladder: correlation with the functions of capsaicin‐sensitive sensory nerves
295. In vivo evidence for tachykininergic transmission using a new NK‐2 receptor selective antagonist. MEN 10376
296. 8]neurokinin A (4–10) a selective NK‐2 tachykinin receptor agonist
297. Motor effect of neurokinins on the rat duodenum: evidence for the involvement of substance K and substance P receptors
298. Tachykinin antagonists inhibit nerve‐mediated contractions in the circular muscle of the human ileum: involvement of NK‐2 receptors
299. 8]neurokinin A(4–10) a selective NK‐2 tachykinin receptor agonist
300. Comparison of the effects of substance P and substance K on blood pressure, salivation and urinary bladder motility in urethane anesthetized rats
301. Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors
302. The sensory‐efferent function of capsaicin‐sensitive sensory neurons
303. Neurokinin receptors in the rat lower urinary tract
304. Tachykinin NK‐1 receptor in the guinea‐pig isolated proximal urethra: characterization by receptor selective agonists and antagonists
305. Affinity of R 396, an NK‐2 tachykinin receptor antagonists, for NK‐2 receptors in preparations from different species
306. NK‐2 receptor agonists and antagonists
307. Immunoblockade by a specific tachykinin antiserum of the noncholinergic contractile responses in the guinea‐pig isolated bronchus
308. Tachykinin receptors in guinea‐pig renal pelvis: activation by exogenous and endogenous tachykinins
309. Activity of spantide I and II at various tachykinin receptors and NK‐2 tachykinin receptor subtypes
310. Tachykinin receptors in the circular muscle of the guinea‐pig ileum
311. Competitive antagonists discriminate between NK‐2 tachykinin receptor subtypes
312. The effect of thiorphan and epithelium removal on contractions and tachykinin release produced by activation of the capsaicin‐sensitive afferents in the guinea‐pig isolated bronchus
313. Sensory nerves, vascular endothelium and neurogenic relaxation of the guinea‐pig isolated pulmonary artery
314. Tachykinin receptors in the guinea‐pig isolated bronchi
315. Tachykinin receptor antagonists and potential clinical applications at peripheral level. Biochem
316. The hamster isolated trachea: a new preparation for studying NK‐2 receptors
317. Tachykinin receptors and noncholinergic bronchoconstriction in the guinea‐pig isolated bronchi
318. Tachykinin antagonists and capsaicin‐induced contraction of the rat isolated urinary bladder: evidence for tachykinin‐mediated cotransmission
319. Human isolated small, intestine: motor responses of the longitudinal muscle to field stimulation and exogenous neuropeptides
320. Human isolated ileum: motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides
321. Further studies on the motor response of the human isolated urinary bladder to tachykinins, capsaicin and electrical field stimulation
322. Activation of micturition reflex by substance P and substance K: indirect evidence for the existence of multiple tachykinin receptors in the rat urinary bladder
323. Evidence for the involvement of substance P in the motor effects of capsaicin on the rat urinary bladder
324. Contractile response of the human isolated urinary bladder to neurokinins: involvement of NK‐2 receptors
325. Tachykinins and calcitonin gene‐related peptide as co‐transmitters in local motor responses produced by sensory nerve activation in the guinea‐pig isolated renal pelvis
326. Motor response of the human isolated colon to capsaicin and its relationship to release of VIP
327. Kassinin” in mammals: the newest tachykinins
328. Neurokinin receptors subtypes mediating the depolarization of neurones in rat and guinea‐pig superior cervical ganglia are different
329. Receptor for sensory neuropeptides in human inflammatory diseases: implications for the effector role of sensory neurons
330. Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues
331. Receptor binding sites for substance P but not substance K or neuromedin K are expressed in high concentrations by arterioles, venules and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease
332. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury
333. Bronchodilatation by tachykinins and capsaicin in the mouse main bronchus
334. Toluene diisocyanate contracts guinea‐pig bronchial smooth muscle by activating capsaicin‐sensitive sensory nerves
335. Substance P‐ CGRP‐ & C‐flanking peptide of neuropeptide Y‐immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis
336. Substance P & somatostatin levels in rheumatoid arthritis, osteoarthritis & psoriatic arthritis synovial fluid
337. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil
338. Disulfiram administration affects substance P‐like immunoreactive & monoaminergic neural systems in rodent brain
339. Biochemical characterization ana anatomical distribution of a major form of unamidated precursor of substance P in rat brain
340. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain
341. Distribution of neurokinin B in the rat brain: immunohistochemistry and in situ hybridization
342. Occurrence & effects of multiple tachykinins, substance P neurokinin A & neuropeptide K in human airways
343. Bronchoconstrictor & hypotensive effects in relation to the pharmacokinetics of tachykinins in the guinea‐pig— evidence for extra‐neuronal cleavage of neuropeptide K to neurokinin A
344. Inhibition of salt appetite in the rat following injection of tachykinins into the medial amygdala
345. The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B
346. cDNA cloning of bovine substance K receptor through oocyte expression system
347. Regulation of epithelial ion transport in the jejunal mucosa of the guinea‐pig by neurokinins
348. Multiple intracellular signaling pathways of the substance P receptor
349. Tachykinin receptors in smooth muscles: a study with agonists (substance P, neurokinin A) & antagonists
350. Undeca‐ & octapeptide antagonists for substance P, a study of the guinea‐pig trachea
351. The effect of neonatal capsaicin treatment on the distribution of neurokinin binding sites in rat bladder
352. Neuroeffector functions of sensory fibres: implications for headache mechanisms & drug actions
353. G protein activation: a receptor independent mode of action for cationic amphiphilic neuropeptides & venom peptides
354. Structure‐activity studies of heptapeptide derivatives related to substance P, neurokinin A, B & other tachykinins on smooth muscles
355. Neurokinin‐induced salivation in the anesthetized rat: a three receptor hypothesis
356. 125I]Bolton Hunter scyliorhinin II: a novel, selective ligand for the tachykinin NK‐3 receptor in rat brain
357. Multiple tachykinin receptors in rat submandibular gland
358. Neutral endopeptidase modulates neurogenic inflammation
359. Direct linkage of three tachykinin receptors to stimulation of both phopshatidylinositol hydrolysis & cyclic ASMP cascades in transfected Chinese hamster ovary cells
360. Mammalian tachykinin receptors
361. Characterization of neurokinin effects & receptor selectivity in human isolated bronchi
362. Tissue selectivity of novel specific & competitive antagonists of neurokinin B on isolated smooth muscles
363. Pharmacological evaluation of the angiotensin, kinin & neurokinin receptors on the rabbit vena cava
364. The rabbit jugular vein is a contractile NK‐1 receptor system
365. Substance K: novel mammalian tachykinin that differs from substance P in its pharmacological profile
366. Nucleotide sequences of cloned cDNAs for two types of bovine substance P precursor
367. Tissue specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing
368. The possible role of substance P in the allergic reaction based on two different provocation models. Int. Arch. Allergy Appl
369. Stimulation of connective tissue cell growth by substance P & substance K
370. Evidence for the co‐existence of multiple NK‐2 tachykinin recepto subtypes in rat bladder
371. Antisera raised against eledoisin & kassinin detect elevated levels of immunoreactive material in plasma & tumor tissues from patients with carcinoid tumors. Regul
372. Regional distribution of substance P neurokinin A & neurokinin B in rat spinal cord, nerve roots & dorsal root ganglia & the effects of dorsal root section & spinal transection
373. Release of substance P from the spinal dorsal horn is enhanced in polyarthritic rats
374. Substance P immunoreactive nerves in airways from asthmatics & nonasthmatics
375. Effect of a tachykinin antagonist on a nociceptive reflex in the isolated spinal cord‐tail preparation of the newborn rat
376. Pain & neurotransmitters
377. Neurokinin agonists differentially affect A9 & A 10 dopamine cells in the rat
378. Behavioural effects of receptor specific substance P agonists
379. The contractile effect of tachykinins on human prostatic urethra: involvement of NK‐2 receptors
380. Neurokinin receptors & mucosal ion transport in porcine jejunum
381. Actinomycin D is a competitive & selective antagonist at NK‐2 tachykinin receptors
382. Further evidence for the existence of NK‐2 tachykinin receptor subtypes
383. Effect of newly developed tachykinin agonists & antagonists on the guinea‐pig isolated gallbladder
384. Effect of newly developed tachykinin agonist & antagonists on the guinea‐pig isolated gallbladder
385. Effect of thiorphan on tachykinininduced potentiation of nerve‐mediated contractions of the rat isolated vas deferens
386. Activity of peptide & non‐peptide antagonists at peripheral NK‐1 tachykinin receptors
387. Specific stimulation of human T lymphocytes by substance P
388. Evidence for substance P as a functional neurotransmitter in guinea‐pig small intestinal mucosa
389. Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis
390. Substance P
391. Research on tachykinins: clinical trends
392. Nerve‐induced tachykinin‐mediated vasodilatation in skeletal muscle is dependent on nitric oxide formation
393. Use of substance P fragments to differentiate substance P receptors of different tissues
394. 2 substance P receptors
395. Effect of selective antagonists at tachykinin NK‐1 & NK‐2 receptors on xylene‐induced cystitis in rats
396. Distribution of neurokinin receptor gene expression in the rat brain
397. The localization of sensory nerve fibers & receptor binding sites for sensory neuropeptides in canine mesenteric lymph nodes
398. Tachykinin antagonists have potent local anaesthetic actions
399. Importance of the C‐terminal amide for biological activity of neurokinin A derivative
400. Multiple tackykinin receptors in guinea‐pig brain. High densities of substance K (neurokinin A) binding sites in substantia nigra
401. Novel substance P antagonist CP‐96,354, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation & to substance P. Neurosci
402. Substance P is released from the endothelium of normal & capsaicin‐treated rat hindlimb vasculature in vivio by increased flow
403. Epithelial & mucosal preparations from canine colon: responses to substance P
404. Peptide antagonists
405. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization
406. Pharmacological receptors for substance P & neurokinins
407. Receptors for substance P & related neurokinins
408. Receptors for substance P. III. Classification by competitive antagonists
409. Substance P‐Structure‐activity studies & the development of antagonists
410. Substance P antagonists showing some selectivity for different receptor types
411. Nonadrenergic noncholinergic (NANC) contractile responses of the guinea‐pig hilar bronchus are partially mediated by tachykinin NK‐2 receptors
412. Classification of tachykinin receptors in guinea‐pig & human airway smooth muscle
413. Depolarizing influences regulate preprotachykinin mRNA in sympathetic neurons
414. 7,9] substance P, an analogue with presumed antagonist actions in the rat
415. Effect of tachykinins on mucus secretion in human bronchi in vitro
416. Involvement of NK‐1 receptors & importance of the N‐terminal sequence of substance P in the stimulation of protein secretion in rat parotid glands
417. The pharmacological profile of a substance P (SP) antagonist. Evidence for the existence of subpopulations of SP receptors
418. Substance P antagonists: a new type of pharacological tool
419. Selectivity & specificity of new, non‐peptide quinuclidine antagonists of substance P. Biochem. Biophys. Res
420. Role of D‐tryptophan for affinity of MEN 10207 tachykinin antagonists at NK‐2 receptors
421. Interaction of amyloid β protein (25–35) with tachykinin receptors
422. A highly selective NK‐2 tachykinin receptor antagonist containing D‐tryptophan
423. Synthesis & biological activity of NN‐2 selective tachykinin antagonists containing D‐tryptophan
424. Structure‐activity studies of neurokinin A
425. Structure‐activity study of the C‐terminals residue of MEN 10207 tachykinin antagonist
426. Endothelium‐dependent relaxant effect of neurokinins on rabbit aorta is mediated by the NK‐1 receptor
427. Localization of tachykinin binding sites (NK‐1, NK‐2, NK‐3 ligands) in the rat brain
428. Characterization of tachykinin receptors in endothelial cells of porcine artery. Neurosci
429. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches
430. Substance P‐evoked release of GABA from isolated spinal cord of the newborn rat
431. Substance P(1–7) antagonizes substance P‐induced aversive behavior in mice
432. Differential effects of substance P analogs on NK‐1 receptor agonists in the mouse spinal cord
433. Substance P
434. Substance Pin sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury
435. Simultaneous release of several tachykinins & CGRP from rat spinal cord slices
436. Release of multiple tachykinins from capsaicin‐sensitive sensory nerves in the lung by bradykinin, histamine, DMPP & vagal nerve stimulation
437. Release of substance P & substance K like immunoreactivities from the isolated per‐fused guinea‐pig lung
438. Molecular characterization of rat substance K receptor & its mRNA. Biochem. Biophys
439. Release of immunoreactive substance P in spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes
440. Effect of substance P & neurokinin A on rat parietal cell function
441. Substance P & neurokinin A are codistributed & colocalized in the porcine gastrointestinal tract
442. Histochemical changes of substance P, FRAP, serotonin & succinic dehydrogenase in the spinal cord of rats with adjuvant arthritis
443. Differences in neurokinin receptor pharmacology between rat & guinea‐pig superior cervical ganglia
444. Substance P in the rat parotid gland: evidence for a dual origin from the otic & trigeminal ganglia
445. Tachykinin gene expression in rat limbic nuclei: modulation by dopamine antagonists
446. Cloning & expression of a rat neuromedin K receptor cDNA
447. Comparison of the presence & actions of substance & neurokinin A in guinea‐pig taenia coli
448. A potent nonpeptide antagonist of the substance P (NK‐l) receptor
449. Effect of CP‐96,345, a nonpeptide substance receptor antagonist, on salivation in rats
450. Sensory neuropeptides & airway function
451. Persistence of intrinsic neurones & possible phenotypic changes after extrinsic denervation of human respiratory tract by heart lung transplantation
452. Characterization of tachykinin receptors in the rat isolated oesophagus
453. Tachykinins can depolarize the rat isolated superior cervical ganglion via NK‐1 receptors
454. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa
455. Autoradiographic demonstration of endothelium‐dependent 125I‐Bolton Hunter substance P binding to dog carotid artery
456. Expression of substance P/neurokinin A‐encoding preprotachykinin messenger RNA in the rat enteric nervous system
457. The NK‐3 tachykinin agonist senktide elicits yawning & chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation
458. Characterization of human ileum NK‐2 receptor stably expressed in chinese hamster ovary cells using NK agonists
459. Characterization of the receptor mediating relaxation to substance P in canine middle cerebral artery: no evidence for involvement of substance P in neurogenically mediated relaxation
460. Molecular cloning of the murine substance K & substance P receptor genes. Eur
461. Impaired defense mechanism to peptic ulcer in the capsaicin desensitized rat
462. Capsaicin‐sensitive non‐cholinergic excitatory innervation of the guinea‐pig tracheobronchial smooth muscle
463. Tachykinin receptor subtypes: cardiovascular roles of tachykinin peptides
464. Role of central tachykinin peptides in cardiovascular regulation in rats
465. Molecular cloning, structural characterization & functional expression of the human substance P receptor
466. Characterization of a high affinity neuropeptide γ binding site in rat duodenum, urinary bladder & vas deferens
467. Neuropeptide K potently stimulates salivary gland secretion & potentiates substance P‐induced salivation
468. γ‐Preprotachykinin‐(72–92)‐peptide amide potentiates substance P‐induced salivation
469. Pharmacological & molecular biological studies on the diversity of rat tachykinin NK‐2 receptor subtypes in rat CNS, duodenum, vas deferens & urinary bladder
470. Regional distribution of neuropeptide γ and other tachykinins derived from the substance P gene in the rat
471. Levels of neurokinin A, neurokinin B and substance P in rabbit iris sphincter muscle. Japn
472. Distribution and localization of neurokinin A‐like immunoreactivity and neurokinin B‐like immunoreactivity in rat peripheral tissue. Regul
473. Neuropeptide K: isolation, structure and biological activities of a novel brain tachykinin. Biochem
474. 3 receptors controlling nonadrenergic noncholinergic contractions of the guinea‐pig isolated ileum
475. Isolation and characterization of neurokinin A, neurokinin A (3–10) and neurokinin A (4–10) from a neutral water extract of a metastatic ileal carcinoid tumor
476. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients
477. Neurokinin A increases short‐circuit current across rat colonic mucosa: a role for vasoactive intestinal polypeptide
478. Heterogeneity of tachykinin‐like immunoreactive peptides in rat spinal cord and dorsal root ganglia
479. A novel radioimmunoassay for neuromedin K. I. Absence of neuromedin K‐like immunoreactivity in guinea‐pig ileum and urinary bladder. II. Heterogeneity of tachykinins in guinea‐pig tissues. Regul
480. Detection of N‐terminally extended substance P but not of substance P in human cerebrospinal fluid
481. N‐terminally extended substance P is released together with substance P from rat spinal cord. Regul
482. Neuropeptide K is present in human cerebrospinal fluid
483. 9]SP in rat brain and guinea‐pig ileum
484. Tissue distribution and quantification of the mRNA for three rat tachykinin receptors. Eur
485. Neuropeptides and theirPeptidases
486. The selective NK‐2 receptor antagonist MEN 10,376 inhibits synaptic excitation of dorsal horn neurones evoked by C‐fibre activation in the in vitro rat spinal cord
487. Comparison of the effects of neuropeptide K and neuropeptide y with neurokinin A at NK‐2 receptors in the hamster urinary bladder. Naunyn Schmiedeberg's Arch
488. Multiple NK‐2 receptor subtypes are suggested by physiological and biochemical studies with neurokinin A (NKA) analogues and antagonists
489. Characterization of a tachykinin peptide NK‐2 receptor transfected into murine fibroblast N82 cell
490. Substance P receptors on canine chief cells: localization, characterization and function
491. An unidentified depressor substance in certain tissue extracts
492. Effects of substance P on the response of guinea‐pig vas deferens to transmural nerve stimulation
493. Substance P enhances interferon‐7 production by human peripheral blood mononuclear cells. Regul
494. Neurogenic mechanisms in control of the rabbit iris sphincter muscle
495. Characterization of neurokinin receptors in the mouse which mediate antidipsogenic activity
496. Role of NK‐2 receptors in the antidipsogenic activity of neurokinins in the mouse
497. Potent and highly selective neurokinin antagonists
498. 11] substance P. Br
499. Light microscopic immunoenzyme and electron microscopic immunogold cytochemistry reveal tachykin in immunoreactivity in Merkel cells of pig skin
500. Tachykinins, CGRP & neuropeptide Y in nerves of the mammalian thymus: interactions with mast cells in autonomic and sensory neuroimmunomodulation? Neurosci
501. The tachykinin neuroimmune connection in inflammatory pain
502. Peptides in the mammalian cardiovascular system
503. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P & endothelin in the rat by a specific inhibitor of nitric oxide formation
504. Development of NK‐2 selective antagonists
505. Characterization of the tachykinin NK‐2 receptor subtype in the rabbit pulmonary artery
506. NK‐1, but not NK‐2, tachykinin receptors mediate plasma extravasation induced by antidromic C‐fiber stimulation in rat hindpaw: demonstrated with NK‐1 antagonist CP 96,345 & the NK‐2 antagonist MEN 10207
507. On the role of NK‐2 tachykinin receptors in the mediation of spinal reflex excitability in the rat
508. On the role of NK‐1 and NK‐2 tachykinin receptors in mediation of spinal cord reflex excitability. Soc
509. Stereospecific effects of a nonpeptidic NK‐I. selective antagonist, CP96345: antinociception in the absence of motor dysfunction
510. Substance P release from knee joint afferent terminals: modulation by opioids
511. Neurotrophic and neurotoxic effect of amyloid β protein: recversal by tachykinin neuropeptides
512. The effects of capsaicin upon electrogenic ion transport in rat descending colon
513. Molecular characterization of a functional cDNA for rat substance P receptor
514. Contribution of substance P to heat‐induced edema in rat paw
515. Substance P induces migration of capillary endothelial cells: a novel NK‐l‐selective receptor mediated activity
516. NK‐1 receptors mediate the proliferative response of human fibroblasts to tachykinins
517. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells
518. Influence of perivascular peptides on endoneurial blood flow & microvascular resistance in the sciatic nerve of the rat